Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.14, in-line with the analyst estimate of $0.14. Revenue for the quarter came in at $47 million versus the consensus estimate of $47.7 million.Meridian Bioscience reaffirmed FY2017 guidance.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.